or Try an Advanced Search...

    Disorders Stocks List

    Symbol Grade Name % Change
    ONCO F Onconetix, Inc. 4.63
    PXMD F PaxMedica, Inc. -49.47
    SEEL F Seelos Therapeutics, Inc. 0.00
    IONS F Ionis Pharmaceuticals, Inc. -4.12
    REGN F Regeneron Pharmaceuticals, Inc. 0.15
    VTGN F VistaGen Therapeutics, Inc. -3.07
    FULC F Fulcrum Therapeutics, Inc. -0.67
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Medical Care Facilities Medical Instruments & Supplies
    Related Stock Lists: Medicine Biopharmaceutical Epilepsy Alzheimer's Disease Anemia Anticonvulsants Clinical Medicine Disease Genodermatoses Hematology Hematopathology Hypertension Kidney Failure Organ Systems Pain Parkinson's Disease Pharmaceutical Psychiatric Diagnosis Syndromes Acid

    Related ETFs - A few ETFs which own one or more of the above listed Disorders stocks.

    Symbol Grade Name Weight
    SURI D Simplify Exchange Traded Funds Simplify Propel Opportunities ETF 8.7
    TPMN A The Timothy Plan Timothy Plan Market Neutral ETF 5.66
    DIVP A Cullen Enhanced Equity Income ETF 2.67
    HRTS F Tema Cardiovascular and Metabolic ETF 2.1
    BLCV A BlackRock Large Cap Value ETF 1.99
    View all Disorders ETFs...
    Compare ETFs
    Compare DIVP to BLCV Compare DIVP to HRTS Compare SURI to BLCV

        Disorders Stocks Recent News

        Date Stock Title
        Nov 21 IONS Why Is Ionis Pharmaceuticals, Inc. (IONS) Among the Worst Performing Biotech Stocks in 2024?
        Nov 20 IONS Ionis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right Now
        Nov 19 REGN Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now
        Nov 19 REGN Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference (Transcript)
        Nov 19 REGN Regeneron: The Biotech Stock To Buy Now
        Nov 19 REGN Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3
        Nov 18 REGN FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
        Nov 18 IONS Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks
        Nov 15 REGN FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
        Nov 15 REGN Regeneron, Sanofi say resubmitted application to expand Dupixent label accepted in U.S.
        Nov 15 FULC Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023)
        Nov 15 REGN Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Medical Care Facilities Medical Instruments & Supplies
        Related Stock Lists: Medicine Biopharmaceutical Epilepsy Alzheimer's Disease Anemia Anticonvulsants Clinical Medicine Disease Genodermatoses Hematology Hematopathology Hypertension Kidney Failure Organ Systems Pain Parkinson's Disease Pharmaceutical Psychiatric Diagnosis Syndromes Acid
        Disorders

        Disorder may refer to randomness, non-order, or no intelligible pattern. Disorder may also refer to:

        More about Disorders
        Browse All Tags